Butterfly Network, Inc. Q3 2026 Earnings Call - BUTTERFLY NETWORK INC

Financial Performance:

• Q3 2026 revenue reached $32.6 million, a 52% year-over-year increase, surpassing the top end of guidance by 9%.
• Core POCUS revenue was $21.5 million (+5% YoY), while Embedded revenue surged $11.1 million, representing over 1,000% YoY growth.
• Gross profit hit a record $23.8 million, driven by high-margin Embedded revenue, a tariff refund, and operational discipline; adjusted gross margin improved to 73% from 64% previously.
• Adjusted EBITDA loss narrowed to $1.2 million (85% improvement YoY), with cash flow usage reduced to $2.4 million from $3.9 million the prior year.
• Cash and cash equivalents stood at $122 million at quarter-end; probe unit sales increased 5% overall, with US unit sales up 9%.

Guidance and Future Outlook:

• Full-year 2026 revenue guidance raised to $123–$126 million (previously $119–$123 million), implying Q4 revenue of $31–$34 million.
• Full-year 2026 adjusted EBITDA loss guidance lowered to $12–$15 million (previously $20–$22 million), implying a Q4 loss of $3–$6 million.
• Management reaffirmed the goal to achieve adjusted EBITDA and cash flow positivity by 2028.
• Q4 2027 guidance will be provided at the JPMorgan conference; future Embedded revenue trajectory is expected to remain robust with potential for significant upside from new partnerships.
• Home and community care revenue is expected to grow throughout 2027 and become meaningful in 2028.

Business Segments and Product Lines:

• Core POCUS: U.S. HHS business grew 15%; secured 15 new enterprise deals (five seven-figure TCV, ten six-figure TCV) driven by Compass AI adoption. FedRAMP authorization enables federal government scaling. VCOM partnership will equip 670 students annually with Butterfly probes.
• Embedded: Added three new partners (Merge Labs, Bridge Neurotech, and one stealth BCI firm); Mendera launched a handheld robotic system using Butterfly tech. The Apollo chip (4th gen) is in development for Physical AI and high-power processing.
• Product Innovation: Next-generation P5.1 chip launching early 2027 will introduce tissue harmonics, surpassing image quality parity with competitors. A limited wearable form factor batch is being released to co-development partners.
• Ecosystem: Signed five new "Garden" partners; DeepEcho launched the first international AI fetal imaging app.

Market and Competitive Landscape:

• U.S. market share in POCUS is reportedly double that of any international region, with health systems increasingly recognizing the need for centralized data management via Compass AI.
• International performance dipped 5% YoY due to timing shifts and inventory issues; a strategic pivot to an enterprise-focused "U.S. playbook" is being implemented globally to improve Q4 2026 and 2027 performance.
• Management notes that some smaller competitors are struggling and larger incumbents are pulling back from certain markets, viewing this as an opportunity for Butterfly to expand.
• The company holds 600–700 patents, creating a significant technological moat in semiconductor-based ultrasound.

Risks and Challenges:

• International Headwinds: Current softness in international markets and reliance on distributors require a strategic shift to direct enterprise sales.
• Revenue Lumpiness: Embedded revenue is milestone-based and lumpy, making quarter-to-quarter guidance challenging; the company advises against extrapolating single large deals.
• Regulatory and Competitive: While FedRAMP was achieved, competition in the broader ultrasound market is expected to intensify as the space matures.
• Execution Risks: Scaling the "home and community care" segment and integrating the IQ Station cart form factor for 2028 market entry carry execution timelines.

Management Commentary and Tone:

• Tone is highly confident and optimistic, with CEO Joe DeVivo describing the business as having "durable and compounding" revenue streams.
• Management emphasizes a shift from hardware sales to a platform model driven by software (Compass AI), education (VCOM), and ecosystems (Garden/Embedded).
• CFO John Doherty stressed financial discipline, noting that the new ATM facility is proactive "corporate housekeeping" with no immediate need for capital.
• The "Flywheel" strategy is highlighted as key, integrating core POCUS, Compass AI, education, and embedded partners to expand the total addressable market.

Analyst Questions and Answers:

• Enterprise Deal Timing: Deals typically start with software deployment followed by phased probe sales over 1–2 years rather than "big bang" hardware purchases.
• Embedded Revenue Guidance: Mid-Journey remains foundational but undisclosed; new deals like Merge are contributing significantly. Management maintains conservative guidance but expects the 2027 embedded trajectory to match or exceed current levels.
• International Strategy: Shifting from distributor-led clinician sales to an institutional/enterprise model similar to the U.S. is expected to bear fruit in Q4 and 2027; this is a capital-efficient investment rather than massive new spend.
• Compass AI Utility: Compass AI is designed to be hardware-agnostic, solving compliance and data management issues for hospitals using mixed POCUS hardware (including competitors), serving as a "land and expand" platform for future Butterfly hardware.
• Home Care: Initial focus is on congestive heart failure to reduce readmissions; data on cost savings will be shared without violating partner confidentiality.
• Physical AI & Wearables: The Apollo chip will enable on-device AI processing for immediate clinical feedback, and wearables will target specific subspecialties (cardiac, abdominal) via partner innovation.

Other Key Points:

• Filed a new universal shelf registration (Form S-3) and established an at-the-market (ATM) equity program for up to $150 million over three years.
• R&D expenses increased 17% YoY to support the Apollo chip, wearable form factors, and embedded partner development.
• The company is preparing to enter the $8 billion cart-based ultrasound market in 2028 with a semiconductor-based platform.
• CEO emphasized that the company is moving from "program building" to "execution" in home care and embedded commercialization.